Swiss drugmaker <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.roche.com/">Roche</a> </span>can't fulfill need for sub-atomic tests to distinguish dynamic <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">COVID-19 diseases</a></span>, its director revealed to Swiss every day <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.tagesanzeiger.ch/">Tagesanzeiger.</a></span>
<blockquote>"The interest surpasses our creation," <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://en.wikipedia.org/wiki/Christoph_Franz">Christoph Franz</a></span> was cited as saying in Saturday's paper. The choice on where tests were sent to depended, in addition to other things, on contamination rates and the accessibility of indicative gear.</blockquote>
Interest for its immunizer tests, which decide if individuals have ever been contaminated with the coronavirus, can be met as Roche has been boosting creation, he said.

The drugmaker has said that it intends to dramatically increase creation of counter acting agent tests to well more than 100 million per month before the year's over.

<span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.firstpost.com/tech/science/roches-arthritis-drug-actemra-fails-to-help-patients-with-early-stage-covid-19-pneumonia-in-italian-study-8495991.html">Franz said that Roche had begun research on a possible medication to treat COVID-19 however included that these endeavors were at a beginning phase.</a></span>